Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Madan Gopal Kundu"'
Autor:
Erika P. Hamilton, Shekeab Jauhari, Kathleen N. Moore, Brian I. Rini, Robert McLeod, Jie Lin, Nanae Izumi, Madan Gopal Kundu, Yusuke Myobatake, Abderrahmane Laadem, Yutaka Noguchi, Julius Kirui, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 40:3002-3002
3002 Background: Cadherin 6 (CDH6) is part of the cadherin family, which is involved with cell-cell adhesion, organ development, and epithelial-mesenchymal transition. CDH6 is found to be overexpressed in various cancers, particularly RCC and OVC. DS
Autor:
Suzanne George, Michael C. Heinrich, Neeta Somaiah, Brian Andrew Van Tine, Robert McLeod, Abderrahmane Laadem, Ben Cheng, Satoshi Nishioka, Madan Gopal Kundu, Xiaozhong Qian, Yvonne Y. Lau, Brittany Tran, Prasanna Kumar, Ololade Dosunmu, Julia Shi, Yoichi Naito
Publikováno v:
Journal of Clinical Oncology. 40:11512-11512
11512 Background: GPR20 is selectively and abundantly expressed in GISTs, the most common sarcoma of digestive tract. DS-6157a is an anti-GPR20 antibody-drug conjugate with a novel tetrapeptide-based linker and DNA topoisomerase I inhibitor exatecan
Autor:
Bridget Riley-Gillis, Véronique Diéras, Shannon Puhalla, Meijing Wu, Erin Murphy, Yuan Yuan, Hyo S. Han, Vered Stearns, Madan Gopal Kundu, Michael Friedlander, David Maag, Jean-Pierre M. Ayoub, Hans Wildiers, Cyril Ramathal, Teresa Helsten, Banu Arun, Bella Kaufman, Christine K. Ratajczak
Publikováno v:
Journal of Clinical Oncology. 38:1097-1097
1097 Background: In BROCADE3 (NCT02163694), addition of the PARP inhibitor (PARPi) V to CP improved PFS in patients (pts) with g BRCA-associated advanced breast cancer (hazard ratio 0.71 [95% CI 0.57–0.88], p = 0.002). Reversion mutations may accou
Autor:
Matthew W. Dudley, Hyo S. Han, Bruce A. Bach, Hans Wildiers, Michael Friedlander, Madan Gopal Kundu, Bella Kaufman, Jean-Pierre M. Ayoub, Christine K. Ratajczak, Banu Arun, Véronique Diéras, David Maag, Shannon Puhalla
Publikováno v:
Journal of Clinical Oncology. 38:1091-1091
1091 Background: In BROCADE3 (NCT02163694), addition of PARP inhibitor V to CP resulted in improved progression-free survival (PFS) (HR 0.71 [95% CI 0.57−0.88], p=0.002) in patients (pts) with advanced HER2-negative breast cancer and g BRCA1/2 muta